Executive Team

Our best-in-class leadership team is expanding, increasing every day the depth of experience and perspective on our growing company. Meet the team:

Steve Saviuk

Mr. Saviuk started his career in accounting at KPMG. He quickly moved to venture capital investing through Manitex Capital Inc., a TSXV-listed company he co-founded over 30 years ago, and which still actively invests in emerging companies with a focus on the life science, renewable energy and sustainable resource sectors. Mr. Saviuk is President and CEO of Manitex Capital inc.

Mr. Saviuk co-founded Valeo Pharma in 2003 and has since served as its President and CEO. Mr. Saviuk transformed Valeo Pharma from its early years as an in-licensor of established brands to a fast growing full service Canadian pharmaceutical company and was also instrumental in the sale of certain assets to Valeant Canada. In addition to Mr. Saviuk’s executive management experience, he is well acquainted with key corporate governance issues having served on numerous boards of both public and private companies.

Mr. Saviuk hold a degree in Business (B.Comm) from Concordia University (Montreal, Qc).

Pascal Tougas

Pascal is a seasoned senior pharmaceutical executive with a strong finance profile. With a passion for driving value in organizations, Pascal has a track record of collaboration, forward strategic thinking, operational and financial business acumen, and execution. Pascal spent 11 years at Sanofi Canada in roles of increasing responsibility where he served as Country Head, Trade and Revenue Management, Chief Financial Officer Canada interim and Director Controlling and Operations Canada amongst others. Pascal holds a bachelor’s degree in business administration from the HEC Montreal and a CPA designation.

Kyle Steiger

Kyle Steiger is a life science & pharmaceutical industry veteran with over 20 years of proven and diverse experience across specialty pharma, biologic primary care, medical devices, OTC, health policy and reimbursement. Prior to joining Valeo, Kyle served as Vice-President Commercial services at Ashfield, part of UDG Healthcare, and spent more than 19 years at Novartis in various executive positions such as Vice-President Ophthalmology, Vice-President Primary Care and Franchise Head Hematology. Kyle holds a Bachelor of Arts (B.A.), History & Political Science from Brock University.

Guy-Paul Allard

Mr. Allard is a lawyer and Member of the Quebec Bar since 1996. In addition to his position with Valeo Pharma, Mr. Allard is Vice-President, Legal Affairs and Corporate Secretary for Manitex Capital Inc. and Ortho Regenerative Technologies Inc., two affiliates of Valeo Pharma, since April 2016. From 2007 to 2016, he was Partner and Counsel at Dentons, a multinational law firm where he specialized in corporate finance, securities, and mergers and acquisitions. Throughout his career, he has been counsel to several publicly-listed companies on various matters.

Mr. Allard holds a Bachelor’s degree in Business Administration (B.A.A), a Certificate in Law and a Bachelor’s degree in Law (LL.B.) from Laval University (Quebec City).